The competitive position of Senexis relies on the barriers to entry
provided by its intellectual property rights and know-how in the areas
of amyloid preparation and biochemistry, assay development, medicinal chemistry, amyloid
pathology and clinical development. In particular, the broad and
defensible portfolio of “composition-of-matter” patents protects a
series of compounds that inhibit the misfolding, aggregation and
associated toxicity of amyloid-forming proteins. The portfolio of
compounds comprises novel molecules generated by the Company’s
proprietary assay platforms and discovery tools, along with in-licensed
compounds that Senexis has continued to develop further. This approach
provides multiple product opportunities for potentially treating all
diseases of amyloid-related toxicity derived from an efficient and
cost-effective discovery platform.

Senexis operates on a “semi-virtual” basis, in which only the
preparation of toxic forms of amyloid and the proprietary core in vitro assays are run internally. The Company
has been established in a self-contained small operational base of 1,700
square feet in the Bioincubator Building on the Babraham Research Campus
in Cambridge since June 2004. Medicinal Chemistry, DMPK and some of our
efficacy testing of our novel molecules are carried out through
collaborations with contract research organisations and academic groups. The Company's registered office is located at
Babraham Hall on the Campus, a photograph of which is shown to the
right.